Viskaan Pharma Profile
Key Indicators
- Authorised Capital ₹ 0.20 M
- Paid Up Capital ₹ 0.20 M
- Company Age 37 Year, 8 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 0.10 M
- Revenue Growth -35.58%
- Profit Growth -35.36%
- Ebitda -16.37%
- Net Worth 9.88%
- Total Assets -31.76%
About Viskaan Pharma
Viskaan Pharma Pvt Ltd (VPPL) is a leading Private Limited Indian Non-Government Company incorporated in India on 02 June 1987 and has a history of 37 years and eight months. Its registered office is in Hyderabad, Telangana, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.20 M and a paid-up capital of Rs 0.20 M.
The company currently has active open charges totaling ₹0.10 M.
Kadempally Kumar and Kutumba Puppala serve as directors at the Company.
Company Details
- Location
Hyderabad, Telangana, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U01222TG1987PTC007510
- Company No.
007510
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
02 Jun 1987
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Who are the key members and board of directors at Viskaan Pharma?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Kadempally Kumar  | Managing Director | 02-Jun-1987 | Current |
Board Members (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Kutumba Puppala | Director | 31-Aug-1994 | Current |
Financial Performance of Viskaan Pharma.
Viskaan Pharma Pvt Ltd, for the financial year ended 2022, experienced significant reduction in revenue, with a 35.58% decrease. The company also saw a substantial fall in profitability, with a 35.36% decrease in profit. The company's net worth moved up by a moderate rise of 9.88%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Viskaan Pharma?
In 2020, Viskaan Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
₹0.10 M
₹0
Charges Breakdown by Lending Institutions
- Union Bank Of India : 0.01 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 18 Jan 1989 | Union Bank Of India | ₹0.10 M | Open |
How Many Employees Work at Viskaan Pharma?
Unlock and access historical data on people associated with Viskaan Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Viskaan Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Viskaan Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
